Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 3-4/2011

01.12.2011

Cyclooxygenase-2 and Gastric Cancer

verfasst von: Alexandra Thiel, Johanna Mrena, Ari Ristimäki

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2011

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer remains a leading cause of cancer-related deaths worldwide, although its incidence has been steadily declining during recent decades. Expression of cyclooxygenase-2 (COX-2) is elevated in gastric carcinomas and in their precursor lesions. COX-2 expression associates with reduced survival in gastric cancer patients, and it has also been shown to be an independent factor of poor prognosis. Several molecular mechanisms are involved in the regulation of COX-2 expression in gastric cancer cell lines, including signal transduction pathways activated by Helicobacter pylori. In gastric tumor models in vivo the role of COX-2 seems to be predominantly to facilitate tumor promotion and growth.
Literatur
1.
Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893–2917.CrossRef
2.
Crew, K. D., & Neugut, A. I. (2006). Epidemiology of gastric cancer. World Journal of Gastroenterology, 12(3), 354–362.PubMed
3.
Shikata, K., Doi, Y., Yonemoto, K., Arima, H., Ninomiya, T., Kubo, M., et al. (2008). Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: The hisayama study. American Journal of Epidemiology, 168(12), 1409–1415.PubMedCrossRef
4.
Vogiatzi, P., Vindigni, C., Roviello, F., Renieri, A., & Giordano, A. (2007). Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. Journal of Cellular Physiology, 211(2), 287–295.PubMedCrossRef
5.
Yin, M., Hu, Z., Tan, D., Ajani, J. A., & Wei, Q. (2009). Molecular epidemiology of genetic susceptibility to gastric cancer: Focus on single nucleotide polymorphisms in gastric carcinogenesis. American Journal of Translational Research, 1(1), 44–54.PubMed
6.
Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., et al. (2009). The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377–386.PubMedCrossRef
7.
Menter, D. G., Schilsky, R. L., & DuBois, R. N. (2010). Cyclooxygenase-2 and cancer treatment: Understanding the risk should be worth the reward. Clinical Cancer Research, 16(5), 1384–1390.PubMedCrossRef
8.
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., & Heath, C. W., Jr. (1993). Aspirin use and risk of fatal cancer. Cancer Research, 53(6), 1322–1327.PubMed
9.
Schreinemachers, D. M., & Everson, R. B. (1994). Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5(2), 138–146.PubMedCrossRef
10.
Zaridze, D., Borisova, E., Maximovitch, D., & Chkhikvadze, V. (1999). Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia. International Journal of Cancer, 82(4), 473–476.CrossRef
11.
Langman, M. J., Cheng, K. K., Gilman, E. A., & Lancashire, R. J. (2000). Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ, 320(7250), 1642–1646.PubMedCrossRef
12.
Akre, K., Ekstrom, A. M., Signorello, L. B., Hansson, L. E., & Nyren, O. (2001). Aspirin and risk for gastric cancer: A population-based case-control study in Sweden. British Journal of Cancer, 84(7), 965–968.PubMedCrossRef
13.
Abnet, C. C., Freedman, N. D., Kamangar, F., Leitzmann, M. F., Hollenbeck, A. R., & Schatzkin, A. (2009). Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a meta-analysis. British Journal of Cancer, 100(3), 551–557.PubMedCrossRef
14.
Ristimäki, A., Honkanen, N., Jänkälä, H., Sipponen, P., & Härkönen, M. (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Research, 57(7), 1276–1280.PubMed
15.
Saukkonen, K., Rintahaka, J., Sivula, A., Buskens, C. J., Van Rees, B. P., Rio, M. C., et al. (2003). Cyclooxygenase-2 and gastric carcinogenesis. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 111(10), 915–925.PubMedCrossRef
16.
Lim, H. Y., Joo, H. J., Choi, J. H., Yi, J. W., Yang, M. S., Cho, D. Y., et al. (2000). Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clinical Cancer Research, 6(2), 519–525.PubMed
17.
Saukkonen, K., Nieminen, O., van Rees, B., Vilkki, S., Härkönen, M., Juhola, M., et al. (2001). Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clinical Cancer Research, 7(7), 1923–1931.PubMed
18.
van Rees, B. P., Saukkonen, K., Ristimaki, A., Polkowski, W., Tytgat, G. N., Drillenburg, P., et al. (2002). Cyclooxygenase-2 expression during carcinogenesis in the human stomach. The Journal of Pathology, 196(2), 171–179.PubMedCrossRef
19.
Konturek, P. C., Konturek, S. J., & Brzozowski, T. (2009). Helicobacter pylori infection in gastric cancerogenesis. Journal of Physiology and Pharmacology, 60(3), 3–21.PubMed
20.
Guo, X. L., Wang, L. E., Du, S. Y., Fan, C. L., Li, L., Wang, P., et al. (2003). Association of cyclooxygenase-2 expression with hp-cagA infection in gastric cancer. World Journal of Gastroenterology, 9(2), 246–249.PubMed
21.
Iwamoto, J., Mizokami, Y., Takahashi, K., Matsuoka, T., & Matsuzaki, Y. (2008). The effects of cyclooxygenase2-prostaglandin E2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells. Helicobacter, 13(3), 174–182.PubMedCrossRef
22.
Sheehan, K. M., Sheahan, K., O’Donoghue, D. P., MacSweeney, F., Conroy, R. M., Fitzgerald, D. J., et al. (1999). The relationship between cyclooxygenase-2 expression and colorectal cancer. Journal of the American Medical Association, 282(13), 1254–1257.PubMedCrossRef
23.
Buskens, C. J., Van Rees, B. P., Sivula, A., Reitsma, J. B., Haglund, C., Bosma, P. J., et al. (2002). Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 122(7), 1800–1807.PubMedCrossRef
24.
Ristimäki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research, 62(3), 632–635.PubMed
25.
Erkinheimo, T. L., Lassus, H., Sivula, A., Sengupta, S., Furneaux, H., Hla, T., et al. (2003). Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Research, 63(22), 7591–7594.PubMed
26.
Juuti, A., Louhimo, J., Nordling, S., Ristimaki, A., & Haglund, C. (2006). Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. Journal of Clinical Pathology, 59(4), 382–386.PubMedCrossRef
27.
Mrena, J., Wiksten, J. P., Thiel, A., Kokkola, A., Pohjola, L., Lundin, J., et al. (2005). Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clinical Cancer Research, 11(20), 7362–7368.PubMedCrossRef
28.
Murata, H., Kawano, S., Tsuji, S., Tsuji, M., Sawaoka, H., Kimura, Y., et al. (1999). Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. The American Journal of Gastroenterology, 94(2), 451–455.PubMedCrossRef
29.
Yamamoto, H., Itoh, F., Fukushima, H., Hinoda, Y., & Imai, K. (1999). Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. International Journal of Cancer, 84(4), 400–403.CrossRef
30.
Chen, J. H., Liu, T. Y., Wu, C. W., & Chi, C. W. (2001). Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: Cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression. Medical Hypotheses, 57(4), 503–505.PubMedCrossRef
31.
Lee, T. L., Leung, W. K., Lau, J. Y., Tong, J. H., Ng, E. K., Chan, F. K., et al. (2001). Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Letters, 168(2), 133–140.PubMedCrossRef
32.
Leung, W. K., To, K. F., Ng, Y. P., Lee, T. L., Lau, J. Y., Chan, F. K., et al. (2001). Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. British Journal of Cancer, 84(3), 335–339.PubMedCrossRef
33.
Joo, Y. E., Oh, W. T., Rew, J. S., Park, C. S., Choi, S. K., & Kim, S. J. (2002). Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion, 66(4), 222–229.PubMedCrossRef
34.
Joo, Y. E., Rew, J. S., Seo, Y. H., Choi, S. K., Kim, Y. J., Park, C. S., et al. (2003). Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. Journal of Clinical Gastroenterology, 37(1), 28–33.PubMedCrossRef
35.
Li, H. X., Chang, X. M., Song, Z. J., & He, S. X. (2003). Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma. World Journal of Gastroenterology, 9(4), 674–677.PubMed
36.
Shi, H., Xu, J. M., Hu, N. Z., & Xie, H. J. (2003). Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World Journal of Gastroenterology, 9(7), 1421–1426.PubMed
37.
Yu, H. G., Li, J. Y., Yang, Y. N., Luo, H. S., Yu, J. P., Meier, J. J., et al. (2003). Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Letters, 195(1), 43–51.PubMedCrossRef
38.
Okano, H., Shinohara, H., Miyamoto, A., Takaori, K., & Tanigawa, N. (2004). Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clinical Cancer Research, 10(20), 6938–6945.PubMedCrossRef
39.
Sung, J. J., Leung, W. K., Go, M. Y., To, K. F., Cheng, A. S., Ng, E. K., et al. (2000). Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. The American Journal of Pathology, 157(3), 729–735.PubMedCrossRef
40.
Rajnakova, A., Moochhala, S., Goh, P. M., & Ngoi, S. (2001). Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Letters, 172(2), 177–185.PubMedCrossRef
41.
Tatsuguchi, A., Matsui, K., Shinji, Y., Gudis, K., Tsukui, T., Kishida, T., et al. (2004). Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Human Pathology, 35(4), 488–495.PubMedCrossRef
42.
Mrena, J., Wiksten, J. P., Kokkola, A., Nordling, S., Ristimaki, A., & Haglund, C. (2010). COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biology, 31(1), 1–7.PubMedCrossRef
43.
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092–1102.PubMedCrossRef
44.
Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., et al. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England Journal of Medicine, 352(11), 1071–1080.PubMedCrossRef
45.
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., et al. (2005). Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. The New England Journal of Medicine, 352(11), 1081–1091.PubMedCrossRef
46.
Marnett, L. J. (2009). The COXIB experience: A look in the rearview mirror. Annual Review of Pharmacology and Toxicology, 49, 265–290.PubMedCrossRef
47.
Feng, G. S., Ma, J. L., Wong, B. C., Zhang, L., Liu, W. D., Pan, K. F., et al. (2008). Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology, 14(28), 4535–4539.PubMedCrossRef
48.
Tendo, M., Yashiro, M., Nakazawa, K., Yamada, N., Sawada, T., Ohira, M., et al. (2006). A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Letters, 244(2), 247–251.PubMedCrossRef
49.
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., et al. (2009). Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prevention Research, 2(4), 310–321.PubMedCrossRef
50.
Yokozaki, H. (2000). Molecular characteristics of eight gastric cancer cell lines established in japan. Pathology International, 50(10), 767–777.PubMedCrossRef
51.
Thiel, A., Heinonen, M., Rintahaka, J., Hallikainen, T., Hemmes, A., Dixon, D. A., et al. (2006). Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. The Journal of Biological Chemistry, 281(8), 4564–4569.PubMedCrossRef
52.
Yeh, T. S., Wu, C. W., Hsu, K. W., Liao, W. J., Yang, M. C., Li, A. F., et al. (2009). The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Research, 69(12), 5039–5048.PubMedCrossRef
53.
Hla, T., & Neilson, K. (1992). Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America, 89(16), 7384–7388.PubMedCrossRef
54.
Lim, J. W., Kim, H., & Kim, K. H. (2001). Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Laboratory Investigation, 81(3), 349–360.PubMedCrossRef
55.
Subramaniam, D., Ramalingam, S., May, R., Dieckgraefe, B. K., Berg, D. E., Pothoulakis, C., et al. (2008). Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: Differential transcriptional and posttranscriptional mechanisms. Gastroenterology, 134(4), 1070–1082.PubMedCrossRef
56.
Brennan, C. M., & Steitz, J. A. (2001). HuR and mRNA stability. Cellular and Molecular Life Sciences: CMLS, 58(2), 266–277.PubMedCrossRef
57.
Oshima, H., Oshima, M., Inaba, K., & Taketo, M. M. (2004). Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. The EMBO Journal, 23(7), 1669–1678.PubMedCrossRef
58.
Shen, H., Sun, W. H., Xue, Q. P., Wu, J., Cheng, Y. L., Ding, G. X., et al. (2006). Influences of helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro. Journal of Gastroenterology and Hepatology, 21(4), 754–758.PubMedCrossRef
59.
Juttner, S., Cramer, T., Wessler, S., Walduck, A., Gao, F., Schmitz, F., et al. (2003). Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: Critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cellular Microbiology, 5(11), 821–834.PubMedCrossRef
60.
Chang, Y. J., Wu, M. S., Lin, J. T., Sheu, B. S., Muta, T., Inoue, H., et al. (2004). Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-src-dependent nuclear factor-kappaB activation. Molecular Pharmacology, 66(6), 1465–1477.PubMedCrossRef
61.
Chang, Y. J., Wu, M. S., Lin, J. T., & Chen, C. C. (2005). Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. Journal of Immunology, 175(12), 8242–8252.
62.
Li, Q., Liu, N., Shen, B., Zhou, L., Wang, Y., Wang, Y., et al. (2009). Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells. Cancer Letters, 278(1), 97–103.PubMedCrossRef
63.
Wu, W. K., Lee, C. W., Cho, C. H., Fan, D., Wu, K., Yu, J., et al. (2010). MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene, 29(43), 5761–5771.PubMedCrossRef
64.
Strillacci, A., Griffoni, C., Sansone, P., Paterini, P., Piazzi, G., Lazzarini, G., et al. (2009). MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Experimental Cell Research, 315(8), 1439–1447.PubMedCrossRef
65.
Wang, H. J., Ruan, H. J., He, X. J., Ma, Y. Y., Jiang, X. T., Xia, Y. J., et al. (2010). MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. European Journal of Cancer, 46(12), 2295–2303.PubMedCrossRef
66.
Hao, Y., Gu, X., Zhao, Y., Greene, S., Sha, W., Smoot, D., et al. (2011). Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila), 4(7), 1073–1083.
67.
Yan, M., Rerko, R. M., Platzer, P., Dawson, D., Willis, J., Tong, M., et al. (2004). 15-hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proceedings of the National Academy of Sciences of the United States of America, 101(50), 17468–17473.PubMedCrossRef
68.
Liu, Z., Wang, X., Lu, Y., Han, S., Zhang, F., Zhai, H., et al. (2008). Expression of 15-PGDH is down-regulated by COX-2 in gastric cancer. Carcinogenesis, 29, 1219–1227.PubMedCrossRef
69.
Thiel, A., Ganesan, A., Mrena, J., Junnila, S., Nykanen, A., Hemmes, A., et al. (2009). 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clinical Cancer Research, 15(14), 4572–4580.PubMedCrossRef
70.
Tatsuwaki, H., Tanigawa, T., Watanabe, T., Machida, H., Okazaki, H., Yamagami, H., et al. (2010). Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Science, 101(2), 550–558.PubMedCrossRef
71.
Tong, M., Ding, Y., & Tai, H. H. (2006). Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis, 27(11), 2170–2179.PubMedCrossRef
72.
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193.PubMedCrossRef
73.
Fu, Y. G., Sung, J. J., Wu, K. C., Wu, H. P., Yu, J., Chan, M., et al. (2005). Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants. Cancer Letters, 224(2), 243–252.PubMedCrossRef
74.
Yao, L., Liu, F., Hong, L., Sun, L., Liang, S., Wu, K., et al. (2011). The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. Journal of Experimental & Clinical Cancer Research, 30, 13.CrossRef
75.
Ding, Y. B., Shi, R. H., Tong, J. D., Li, X. Y., Zhang, G. X., Xiao, W. M., et al. (2005). PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Experimental Oncology, 27(2), 108–113.PubMed
76.
Sun, W. H., Zhu, F., Chen, G. S., Su, H., Luo, C., Zhao, Q. S., et al. (2008). Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Letters, 263(2), 302–311.PubMedCrossRef
77.
Yuan, X. L., Chen, L., Li, M. X., Dong, P., Xue, J., Wang, J., et al. (2010). Elevated expression of Foxp3 in tumor-infiltrating treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clinical Immunology, 134(3), 277–288.PubMedCrossRef
78.
Oshima, H., Matsunaga, A., Fujimura, T., Tsukamoto, T., Taketo, M. M., & Oshima, M. (2006). Carcinogenesis in mouse stomach by simultaneous activation of the wnt signaling and prostaglandin E2 pathway. Gastroenterology, 131(4), 1086–1095.PubMedCrossRef
79.
Oshima, H., Itadani, H., Kotani, H., Taketo, M. M., & Oshima, M. (2009). Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Research, 69(7), 2729–2733.PubMedCrossRef
80.
Oshima, H., Oguma, K., Du, Y. C., & Oshima, M. (2009). Prostaglandin E2, wnt, and BMP in gastric tumor mouse models. Cancer Science, 100(10), 1779–1785.PubMedCrossRef
81.
Oshima, M., Oshima, H., Matsunaga, A., & Taketo, M. M. (2005). Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Research, 65(20), 9147–9151.PubMedCrossRef
82.
Itadani, H., Oshima, H., Oshima, M., & Kotani, H. (2009). Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics, 10, 615.PubMedCrossRef
83.
Oshima, H., Popivanova, B. K., Oguma, K., Kong, D., Ishikawa, T. O., & Oshima, M. (2011). Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Science, 102(4), 713–719.PubMedCrossRef
84.
Oshima, H., Hioki, K., Popivanova, B. K., Oguma, K., Van Rooijen, N., Ishikawa, T. O., et al. (2011). Prostaglandin E 2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology, 140(2), 596–607.e7.PubMedCrossRef
85.
Lefebvre, O., Chenard, M. P., Masson, R., Linares, J., Dierich, A., LeMeur, M., et al. (1996). Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science, 274(5285), 259–262.PubMedCrossRef
86.
Saukkonen, K., Tomasetto, C., Narko, K., Rio, M. C., & Ristimäki, A. (2003). Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Research, 63(12), 3032–3036.PubMed
87.
Thiel, A., Narko, K., Heinonen, M., Hemmes, A., Tomasetto, C., Rio M. C., et al. (in press). Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. International Journal of Cancer.
88.
Udd, L., Katajisto, P., Rossi, D. J., Lepisto, A., Lahesmaa, A. M., Ylikorkala, A., et al. (2004). Suppression of peutz-jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology, 127(4), 1030–1037.PubMedCrossRef
89.
Kanda, N., Seno, H., Kawada, M., Sawabu, T., Uenoyoma, Y., Nakajima, T., et al. (2006). Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. American Journal of Physiology. Gastrointestinal and Liver Physiology, 290(3), G519–G527.PubMedCrossRef
90.
Nam, K. T., Hahm, K. B., Oh, S. Y., Yeo, M., Han, S. U., Ahn, B., et al. (2004). The selective cyclooxygenase-2 inhibitor nimesulide prevents helicobacter pylori-associated gastric cancer development in a mouse model. Clinical Cancer Research, 10(23), 8105–8113.PubMedCrossRef
91.
Leung, W. K., Wu, K. C., Wong, C. Y., Cheng, A. S., Ching, A. K., Chan, A. W., et al. (2008). Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis, 29(8), 1648–1654.PubMedCrossRef
92.
Takasu, S., Tsukamoto, T., Cao, X. Y., Toyoda, T., Hirata, A., Ban, H., et al. (2008). Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice. Cancer Science, 99(12), 2356–2364.PubMedCrossRef
93.
Tian, W., Zhao, Y., Liu, S., & Li, X. (2010). Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. European Journal of Cancer Prevention, 19(4), 288–298.PubMedCrossRef
94.
Leung, W. K., Ng, E. K., Chan, F. K., Chan, W. Y., Chan, K. F., Auyeung, A. C., et al. (2006). Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clinical Cancer Research, 12(15), 4766–4772.PubMedCrossRef
95.
Zhang, L. J., Wang, S. Y., Huo, X. H., Zhu, Z. L., Chu, J. K., Ma, J. C., et al. (2009). Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World Journal of Gastroenterology, 15(22), 2731–2738.PubMedCrossRef
Metadaten
Titel
Cyclooxygenase-2 and Gastric Cancer
verfasst von
Alexandra Thiel
Johanna Mrena
Ari Ristimäki
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 3-4/2011
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9312-1

Weitere Artikel der Ausgabe 3-4/2011

Cancer and Metastasis Reviews 3-4/2011 Zur Ausgabe

OriginalPaper

Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment

OriginalPaper

COX inhibitors directly alter gene expression: role in cancer prevention?

OriginalPaper

Polyunsaturated fatty acid metabolism in prostate cancer

Acknowledgments

Biography—Susan M. Fischer, Ph.D.

OriginalPaper

Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention

OriginalPaper

The cytochrome P450 pathway in angiogenesis and endothelial cell biology

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise